Literature DB >> 729603

Metabolism of procainamide in patients with chronic heart failure, chronic respiratory failure and chronic renal failure.

P du Souich, S Erill.   

Abstract

Fractional hydrolysis and acetylation of procainamide, acetylation of procainamide-derived p-aminobenzoic acid and plasma hydrolysis of procaine were studied in 20 patients with chronic heart failure (CHF), 20 patients with chronic respiratory insufficiency (CRI) and 20 patients with chronic renal failure (RF). The results were compared with those obtained in a group of 20 normal volunteers. Hydrolysis of procainamide and procaine were reduced in patients with CHF and CRI, but not in patients with RF. Moreover, more marked decreases in procainamide and procaine hydrolysis were seen in subgroups with secondary hepatic dysfunction. The diminution of hydrolysis of procainamide was not paralleled by changes in acetylation of procainamide or p-aminobenzoic acid. It is concluded that in patients with hepatic involvement secondary to advanced CHF or CRI, hepatic and plasmatic hydrolysis activity is decreased to a degree equivalent to primary liver failure.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 729603     DOI: 10.1007/bf00560254

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

1.  Metabolism of procainamide in normal and cardiac subjects.

Authors:  E G Giardina; J Dreyfuss; J T Bigger; J M Shaw; E C Schreiber
Journal:  Clin Pharmacol Ther       Date:  1976-03       Impact factor: 6.875

2.  Oxygenation during inhibition of drug metabolism by carbon monoxide or hypoxic hypoxia.

Authors:  M R Montgomery; R J Rubin
Journal:  J Appl Physiol       Date:  1973-10       Impact factor: 3.531

3.  Procainamide dosage schedules, plasma concentrations, and clinical effects.

Authors:  J Koch-Weser; S W Klein
Journal:  JAMA       Date:  1971-03-01       Impact factor: 56.272

4.  Serum cholinesterase deficiency in renal failure.

Authors:  N M Simon; F Del Greco; A A Dietz; H M Rubinstein
Journal:  Trans Am Soc Artif Intern Organs       Date:  1969

5.  Metabolism of procainamide and p-aminobenzoic acid in patients with chronic liver disease.

Authors:  P du Souich; S Erill
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

Review 6.  Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis.

Authors:  G A Ellard
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

7.  Role of blood flow in carbon monoxide- and hypoxic hypoxia-induced alterations in hexobarbital metabolism in rats.

Authors:  R A Roth; R J Rubin
Journal:  Drug Metab Dispos       Date:  1976 Sep-Oct       Impact factor: 3.922

8.  N-Acetylprocainamide levels in patients with end-stage renal failure.

Authors:  T P Gibson; E J Matusik; W A Briggs
Journal:  Clin Pharmacol Ther       Date:  1976-02       Impact factor: 6.875

Review 9.  Cor pulmonale (pulmonary heart disease): present-day status.

Authors:  M I Ferrer
Journal:  Am Heart J       Date:  1975-05       Impact factor: 4.749

10.  Hemodialysis for severe procainamide toxicity: clinical and pharmacokinetic observations.

Authors:  A J Atkinson; F A Krumlovsky; C M Huang; F del Greco
Journal:  Clin Pharmacol Ther       Date:  1976-11       Impact factor: 6.875

View more
  5 in total

1.  Downregulation of hepatic acetylation of drugs in chronic renal failure.

Authors:  Emilie Simard; Judith Naud; Josée Michaud; Francois A Leblond; Alain Bonnardeaux; Chantal Guillemette; Edith Sim; Vincent Pichette
Journal:  J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 10.121

Review 2.  The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence.

Authors:  Arduino A Mangoni; Elzbieta A Jarmuzewska
Journal:  Br J Clin Pharmacol       Date:  2018-10-14       Impact factor: 4.335

Review 3.  Pulmonary disease and drug kinetics.

Authors:  P du Souich; A J McLean; D Lalka; S Erill; M Gibaldi
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics in heart failure. An updated review.

Authors:  F V Shammas; K Dickstein
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

5.  Procaine hydrolysis defect in uraemia does not appear to be due to carbamylation of plasma esterases.

Authors:  R Calvo; R Carlos; S Erill
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.